ENT-21: Orally Available Drug for Treatment of Obesity and Type 2 Diabetes 

ENT-21 is an orally available pro-drug

  • Rapidly converted to ENT-03 in bloodstream

  • Appropriate for daily use

  • May be used as monotherapy or in combination with GLP-1s

  • Identical efficacy as ENT-03

Obesity is prevalent in almost 38% of US adults and type 2 diabetes (T2D) affects approximately 9% of US adults. Obesity reduces lifespan and increases the risk of cardiovascular disease, T2D, Metabolic Dysfunction-Associated Steatohepatitis (MASH), and hypertension. The cost of healthcare, caregiving, and hospice care exceeds $290 billion annually in the US, expected to increase to $1.1 trillion by 2050.

Animal studies with ENT-21 have demonstrated significant weight loss over 28 days with daily oral administration. ENT-21 is a prodrug of ENT-03 and is expected to deliver the same therapeutic benefits while enabling oral dosing.